Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.10, Iss.9, 2001-09, pp. : 1745-1753

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host

By Freeman Richard B

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 9, 2004-09 ,pp. : 2007-2016

Informa Healthcare

Access to resources Recommend Favorite

Cytomegalovirus Infection in Pediatric Immunocompromised Hosts

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 11, Iss. 5, 2011-10 ,pp. : 437-448

Bentham Science Publishers

Access to resources Recommend Favorite

Valganciclovir: A Review of its Use in the Management of CMV Infection and Disease in Immunocompromised Patients

By Cvetković Risto S. Wellington Keri

Drugs, Vol. 65, Iss. 6, 2005-01 ,pp. : 859-878

Adis International

Access to resources Recommend Favorite

Cytomegalovirus treatment options in immunocompromised patients

By Sharland Mike Khare Milind D

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 8, 2001-08 ,pp. : 1247-1257

Informa Healthcare

Access to resources Recommend Favorite

Cytomegalovirus Infection in Immunocompetent and Immunocompromised Individuals - A ReviewCytomegalovirus Infection in Immunocompetent and Immunocompromised Individuals - A Review

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 1, Iss. 2, 2001-08 ,pp. : 179-187

Bentham Science Publishers

Access to resources Recommend Favorite